Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Tohoku J Exp Med ; 255(1): 27-31, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34497165

RESUMEN

Langerhans cell neoplasms, which include Langerhans cell histiocytosis and Langerhans cell sarcoma, are tumors that originate from dendritic cells. Langerhans cell sarcoma is defined as a high-grade neoplasm with overtly malignant cytological features and the Langerhans cell-like phenotype, and generally has a poorer prognosis and more aggressive phenotype than Langerhans cell histiocytosis. Insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3 or IMP3) is an oncofetal protein that is expressed in various cancer types; its expression is often associated with a poor prognosis and aggressive phenotype. Here, we used immunohistochemistry to evaluate IGF2BP3 expression in Langerhans cell neoplasms. IGF2BP3 expression was scored as negative (< 1%) or positive (≥ 1%) by immunohistochemistry. All 4 patients with Langerhans cell sarcoma (100%) and 6 of 22 pediatric (age < 18 years) patients with Langerhans cell histiocytosis (27.3%) had positive results for IGF2BP3; however, 16 of 22 pediatric patients with Langerhans cell histiocytosis (72.7%) and all 15 adult (age ≥ 18 years) patients with Langerhans cell histiocytosis (100%) had a negative result. Among patients with Langerhans cell histiocytosis, IGF2BP3 expression was independent of sex, location, prognosis, and BRAF V600E staining results. Taken together, these results indicate that IGF2BP3 expression may be a helpful marker for distinguishing Langerhans cell sarcoma from Langerhans cell histiocytosis in adult patients.


Asunto(s)
Histiocitosis de Células de Langerhans/metabolismo , Sarcoma de Células de Langerhans/metabolismo , Proteínas de Unión al ARN/metabolismo , Adolescente , Adulto , Biomarcadores/metabolismo , Biomarcadores de Tumor/metabolismo , Niño , Preescolar , Diagnóstico Diferencial , Femenino , Histiocitosis de Células de Langerhans/diagnóstico , Humanos , Inmunohistoquímica , Lactante , Recién Nacido , Sarcoma de Células de Langerhans/diagnóstico , Masculino , Persona de Mediana Edad , Adulto Joven
2.
Virchows Arch ; 479(4): 835-839, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33420834

RESUMEN

Desmoplastic myxoid tumor (DMT), SMARCB1-mutant is a recently proposed brain tumor that occurs in the pineal region of adults. This tumor is characterized by desmoplastic stroma and various degrees of myxoid matrix. Tumor cells with low-grade morphology show polyphenotypic immunoreactivity, and rhabdoid cells are rare. We herein present a case with some uncommon features such as no myxoid stroma and slightly elevated proliferating activity. To date, knowledge on the variety of SMARCB1/INI1-deficient tumors of the central nervous system is gradually increasing, encompassing highly aggressive to slow-growing varieties. DMT, SMARCB1-mutant seems to be relatively benign, but careful attention is necessary because SMARCB1/INI1 deficiency is generally a genetic signature of concern.


Asunto(s)
Tumor Desmoplásico de Células Pequeñas Redondas/genética , Proteína SMARCB1/genética , Adulto , Neoplasias Encefálicas/genética , Proteínas Cromosómicas no Histona/genética , Proteínas de Unión al ADN/genética , Tumor Desmoplásico de Células Pequeñas Redondas/metabolismo , Femenino , Expresión Génica/genética , Regulación Neoplásica de la Expresión Génica/genética , Humanos , Glándula Pineal/patología , Pinealoma/genética , Pinealoma/patología , Tumor Rabdoide/patología , Proteína SMARCB1/metabolismo , Sarcoma/genética , Factores de Transcripción/genética , Transcriptoma/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...